Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials

利用贝叶斯模型检测临床试验中不良事件漏报

阅读:1

Abstract

INTRODUCTION: Safety underreporting is a recurrent issue in clinical trials that can impact patient safety and data integrity. Clinical quality assurance (QA) practices used to detect underreporting rely on on-site audits; however, adverse events (AEs) underreporting remains a recurrent issue. In a recent project, we developed a predictive model that enables oversight of AE reporting for clinical quality program leads (QPLs). However, there were limitations to using solely a machine learning model. OBJECTIVE: Our primary objective was to propose a robust method to compute the probability of AE underreporting that could complement our machine learning model. Our model was developed to enhance patients' safety while reducing the need for on-site and manual QA activities in clinical trials. METHODS: We used a Bayesian hierarchical model to estimate the site reporting rates and assess the risk of underreporting. We designed the model with Project Data Sphere clinical trial data that are public and anonymized. RESULTS: We built a model that infers the site reporting behavior from patient-level observations and compares them across a study to enable a robust detection of outliers between clinical sites. CONCLUSION: The new model will be integrated into the current dashboard designed for clinical QPLs. This approach reduces the need for on-site audits, shifting focus from source data verification to pre-identified, higher risk areas. It will enhance further QA activities for safety reporting from clinical trials and generate quality evidence during pre-approval inspections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。